| Human herpesvirus 1 |
Inhibition |
= |
57.0 |
% |
Evaluated for DNA polymerase inhibition activity against herpes simplex virus-1 (HSV-1) |
CHEMBL1123083 |
| Human herpesvirus 2 |
Inhibition |
= |
10.0 |
% |
Evaluated for DNA polymerase inhibition activity against HeLa cells. |
CHEMBL1123083 |
| Human herpesvirus 1 |
ED50 |
= |
0.5 |
ug ml-1 |
In vitro anti viral activity tested against HSV-1(Schooler) virus on Rabbit kidney cell cultures; 0.5-1.5 |
CHEMBL1123083 |
| Human herpesvirus 2 |
ED50 |
= |
1.0 |
ug ml-1 |
In vitro anti viral activity tested against HSV-2(Curtis) virus on Rabbit kidney cell cultures; 1-3 |
CHEMBL1123083 |
| Human herpesvirus 5 |
ED50 |
|
|
|
In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; NA=Not active at 25 ug/mL |
CHEMBL1123083 |
| Human herpesvirus 3 |
ED50 |
|
|
|
In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; ND=Not done |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
4.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
10.7 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
1.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
7.6 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
0.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
6.7 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
3.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
12.9 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
0.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally; Tested mice 9 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
8.1 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Survivors |
= |
0.0 |
|
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average survival |
= |
6.9 |
day |
Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
1.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
0.15 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
5.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
0.75 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
8.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
2.7 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
9.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
3.45 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
2.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
0.4 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
5.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
1.35 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
6.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
1.4 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Mice with lesions |
= |
9.0 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10 |
CHEMBL1123083 |
| Human herpesvirus 1 |
Average lesion score |
= |
2.75 |
|
Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day. |
CHEMBL1123083 |
| Human herpesvirus 1 |
Inhibition |
= |
54.0 |
% |
Compound was tested for the inhibition of HSV-1 polymerase |
CHEMBL1123186 |
| DNA polymerase alpha subunit |
Inhibition |
= |
10.0 |
% |
Compound was tested for the inhibition of HeLa DNA polymerase |
CHEMBL1123186 |
